JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: AMG319 (also known as ACP319) is a novel, potent, selective, orally bioavailable small molecule inhibitor of PI3Kdelta (phosphoinositide-3 kinase delta) with potential anticancer activity. It was originally developed by Amgen as an anti-inflammatory agent for the treatment of autoimmune conditions such as RA-rheumatoid arthritis, but was subsequently found to be able to inhibit cancer cell proliferation and might potentially be useful for cancer treatment. It inhibits PI3Kdelta with an IC50 of 18 nM, and exhibits > 47-fold selectivity for PI3Kdelta over other PI3Ks.
References: Cell. 1997 Oct 17; 91(2):231-41.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!